In particular, we show that increased expression of GFAT1 results in elevated levels of HBP intermediates, excess O-GlcNAcylation, and more severe RVD in a well validated preclinical model of RV pressure overload and PAH, the MCT rat model. Here, GFPT1 is linked to pulmonary arterial hypertension.